Previous 10 | Next 10 |
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor PR Newswire TEL AVIV, Israel and RALEIGH, N.C , May 9, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a spe...
RedHill has had a busy pandemic which has been distressing for shareholders. RedHill has mastered the art of tiny deals with plentiful future prospects, whether they can ever add up to anything is unsure. RedHill's forward liquidity will be highly challenging. For further de...
Israel-based RedHill Biopharma (NASDAQ:RDHL) said on Monday that its investigational oral COVID therapy opaganib was effective against the Omicron variant and maintained the viability of host cells in lab studies. The in vitro results were based on the tests conducted by The University of Hon...
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro PR Newswire - Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of con...
Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collaborating center ...
RedHill Biopharma Ltd. (RDHL) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Alexandra Okmian Sanderovich - Senior Business Development and Investor Relations Manager Dror Ben-Asher - Chief Executive Officer Guy Goldberg - Chief Business Officer Gilead Raday -...
RedHill press release (NASDAQ:RDHL): FY GAAP EPS of -$0.21 beats by $0.78. Revenue of $85.76M (+33.3% Y/Y) misses by $2.14M. Micha Ben Chorin, Chief Financial Officer at RedHill, added: "We have realigned focus within our 120-person strong customer-facing sales team in the U.S., providin...
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results - Record annual and quarterly revenues of $85.8 and $22.1 mil...
RedHill Biopharma (NASDAQ:RDHL) signed an exclusive license agreement with Kukbo for oral opaganib to treat COVID-19, in South Korea. Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payme...
RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea RedHill to receive $1.5 million upfront and is eligible for up to $5.6 million in milestone payments in addition to royalties on net sales from Kukbo Opaganib's Phase 2/3 clinical data shows improved v...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...